Prospective observational study to asses the insulin resistance (IR) and its impact on sustained virological response in a cohort of HCV-infected patients treated with Pegasys and Copegus.
Phase of Trial: Phase IV
Latest Information Update: 24 Jan 2014
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 08 Apr 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2013 Planned End Date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.